Journal article
Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis
Abstract
OBJECTIVE: To determine the harms of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in people who need lipid-lowering therapy.
METHODS: This systematic review included randomised controlled trials that compared PCSK9 inhibitors with placebo, standard care or active lipid-lowering comparators in people who need lipid-lowering therapy with the follow-up duration of at least 24 weeks. We summarised the relative effects for potential …
Authors
Li J; Du H; Wang Y; Aertgeerts B; Guyatt G; Hao Q; Shen Y; Li L; Su N; Delvaux N
Journal
Heart, Vol. 108, No. 16, pp. 1296–1302
Publisher
BMJ
Publication Date
August 2022
DOI
10.1136/heartjnl-2021-320556
ISSN
1355-6037